drugset / Trial / NCT02758613

A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

NCT02758613

Phase 1 Completed 33 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to investigate the safety and tolerability of the study drug known as baricitinib in healthy Chinese participants. The study will measure how the body absorbs, breaks down and gets rid of baricitinib. The study will last about 20 days, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

Timeline

Start
2016-05
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 2 mg Oral
Subject Baricitinib Small molecule 4 mg Oral
Subject Baricitinib Small molecule 10 mg Oral

Indications

No indication recorded.